Internet Archive Scholar

Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a phase II randomized study for 6 months and follow-up to 24 months [post]

2020 unpublished

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (2.2 MB)
https://web.archive.org/web/20200507234517/https://assets.researchsquare.com/files/rs-18107/v1/manuscript.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL. The file type is application/pdf.

Treatment of autoimmune pulmonary alveolar proteinosis (aPAP) by inhaled granulocytemacrophage colony stimulating factor (GM-CSF) is considered safe and effective. Evidences of benefit from GM-CSG inhalation for mild to moderate aPAP patients are limited. Methods: In this multicenter, randomized, open-labeled clinical trial, 36 aPAP patients with mild to moderate disease severity were randomized into either GM-CSF treatment group or control group. Inhaled GM-CSF was prescribed for 6 months, and
more » ... patients were followed-up for another 18 months without treatment. Physiological features of the patients were analyzed.
doi:10.21203/rs.3.rs-18107/v1 fatcat:744bbde7abf7ld3a7gndl37wka
Open Access
Citation

"Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a phase II randomized study for 6 months and follow-up to 24 months." (2020)